celecoxib has been researched along with Seizures in 11 studies
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib (400) mg was administered orally twice a day until tumor progression or dose-limiting toxicity." | 6.73 | Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. ( Batchelor, T; Desideri, S; Grossman, SA; Hammour, T; Lesser, G; Olson, J; Peereboom, D; Supko, JG; Ye, X, 2008) |
| "Epileptic seizures constitute an important problem in pediatric neurology during the developmental period." | 5.48 | Immunomodulatory effect of Celecoxib on HMGB1/TLR4 pathway in a recurrent seizures model in immature rats. ( Caballero-Chacón, S; Feria-Romero, IA; Morales-Sosa, M; Orozco-Suárez, S; Vega-García, A, 2018) |
| "Methylmalonic acidemias are inherited metabolic disorders characterized by methylmalonate (MMA) accumulation and neurologic dysfunction, including seizures." | 3.78 | Prostaglandin E(2) potentiates methylmalonate-induced seizures. ( Banderó, CR; Bortoluzzi, VT; Bueno, LM; Gomes, AT; Jesse, AC; Mello, CF; Oliveira, MS; Rambo, LM; Salvadori, MG, 2012) |
| "Celecoxib (400) mg was administered orally twice a day until tumor progression or dose-limiting toxicity." | 2.73 | Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. ( Batchelor, T; Desideri, S; Grossman, SA; Hammour, T; Lesser, G; Olson, J; Peereboom, D; Supko, JG; Ye, X, 2008) |
| "Autosomal dominant lateral temporal epilepsy (ADLTE) is an inherited syndrome caused by mutations in the leucine-rich glioma inactivated 1 (LGI1) gene." | 1.48 | Celecoxib Ameliorates Seizure Susceptibility in Autosomal Dominant Lateral Temporal Epilepsy. ( Cao, SL; Cowell, JK; Shao, CY; Shen, Y; Su, LD; Wang, N; Wang, YN; Xie, YJ; Zhou, JH; Zhou, L, 2018) |
| "Epileptic seizures constitute an important problem in pediatric neurology during the developmental period." | 1.48 | Immunomodulatory effect of Celecoxib on HMGB1/TLR4 pathway in a recurrent seizures model in immature rats. ( Caballero-Chacón, S; Feria-Romero, IA; Morales-Sosa, M; Orozco-Suárez, S; Vega-García, A, 2018) |
| "The role of PGE(2) in the convulsions induced by PTZ was further investigated by administering anti-PGE(2) antibodies (4 microg/2 microl, i." | 1.35 | Cyclooxygenase-2/PGE2 pathway facilitates pentylenetetrazol-induced seizures. ( Bohrer, D; Castelli, M; Cavalheiro, EA; Ferreira, J; Fighera, MR; Fiorenza, NG; Furian, AF; Machado, P; Mello, CF; Oliveira, MS; Royes, LF; Veiga, M, 2008) |
| "Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor, COX-2 has been shown to be upregulated by convulsive nerve activity." | 1.32 | Anticonvulsant action of celecoxib (alone and in combination with sub-threshold dose of phenytoin) in electroshock induced convulsion. ( Malhotra, S; Pandhi, P; Shafiq, N, 2003) |
| "Celecoxib was studied in the kainate-induced seizure model in the rat, a model of direct central prostaglandin induction, to determine whether it can act directly in the CNS." | 1.31 | Pharmacology of celecoxib in rat brain after kainate administration. ( Ciceri, P; Isakson, PC; Leahy, KM; Seibert, K; Shaffer, AF; Smith, WG; Woerner, MB; Zhang, Y, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, L | 2 |
| Su, LD | 1 |
| Cao, SL | 1 |
| Xie, YJ | 1 |
| Wang, N | 1 |
| Shao, CY | 1 |
| Wang, YN | 1 |
| Zhou, JH | 1 |
| Cowell, JK | 1 |
| Shen, Y | 1 |
| Morales-Sosa, M | 1 |
| Orozco-Suárez, S | 1 |
| Vega-García, A | 1 |
| Caballero-Chacón, S | 1 |
| Feria-Romero, IA | 1 |
| Tayal, V | 1 |
| Kalra, BS | 1 |
| Chawla, S | 1 |
| Salvadori, MG | 1 |
| Banderó, CR | 1 |
| Jesse, AC | 1 |
| Gomes, AT | 1 |
| Rambo, LM | 1 |
| Bueno, LM | 1 |
| Bortoluzzi, VT | 1 |
| Oliveira, MS | 2 |
| Mello, CF | 2 |
| Ciceri, P | 1 |
| Zhang, Y | 1 |
| Shaffer, AF | 1 |
| Leahy, KM | 1 |
| Woerner, MB | 1 |
| Smith, WG | 1 |
| Seibert, K | 1 |
| Isakson, PC | 1 |
| Shafiq, N | 1 |
| Malhotra, S | 1 |
| Pandhi, P | 1 |
| Gobbo, OL | 1 |
| O'Mara, SM | 1 |
| Yoshino, T | 1 |
| Noguchi, M | 1 |
| Okutsu, H | 1 |
| Kimoto, A | 1 |
| Sasamata, M | 1 |
| Miyata, K | 1 |
| Furian, AF | 1 |
| Royes, LF | 1 |
| Fighera, MR | 1 |
| Fiorenza, NG | 1 |
| Castelli, M | 1 |
| Machado, P | 1 |
| Bohrer, D | 1 |
| Veiga, M | 1 |
| Ferreira, J | 1 |
| Cavalheiro, EA | 1 |
| Grossman, SA | 1 |
| Olson, J | 1 |
| Batchelor, T | 1 |
| Peereboom, D | 1 |
| Lesser, G | 1 |
| Desideri, S | 1 |
| Ye, X | 1 |
| Hammour, T | 1 |
| Supko, JG | 1 |
| Toscano, CD | 1 |
| Ueda, Y | 1 |
| Tomita, YA | 1 |
| Vicini, S | 1 |
| Bosetti, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pharmacokinetic Study of the Interaction Between Celecoxib and Anticonvulsant Drugs in Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Radiation Therapy[NCT00068770] | Phase 2 | 35 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to EORTC trail showed TMZ & RT conferred significant survivial in this population) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
subjects will take one dose of celecoxib and will then have 6 hours of blood draws, day 2 subject will take 2 doses of celecoxib 8 hours apart with 2 additional blood samples, one hour apart. Subject, will continue to take 2 doses of celecoxib for 6 weeks, with a sample (PK) drawn every week prior to the first dose of the week. Comparison of Cmax of Celecoxib is reported (NCT00068770)
Timeframe: First dose of celecoxib through completion of radiation, 6 weeks.
| Intervention | (ng/ml) (Geometric Mean) |
|---|---|
| nonp450 | 1752 |
| p450 | 1813 |
duration of survival when celecoxib is administered concurrently with radiation in pts with newly diagnosed glioblastoma multiforme (NCT00068770)
Timeframe: date pt started treatment to date pt last known alive
| Intervention | months (Mean) |
|---|---|
| p450 ( +EIASD) | 11.5 |
| nonp450 (-EIASD) | 16 |
1 trial available for celecoxib and Seizures
| Article | Year |
|---|---|
Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; | 2008 |
10 other studies available for celecoxib and Seizures
| Article | Year |
|---|---|
Celecoxib Ameliorates Seizure Susceptibility in Autosomal Dominant Lateral Temporal Epilepsy.
Topics: Action Potentials; Animals; Anticonvulsants; Celecoxib; Cells, Cultured; Cerebral Cortex; Cyclooxyge | 2018 |
Immunomodulatory effect of Celecoxib on HMGB1/TLR4 pathway in a recurrent seizures model in immature rats.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Female; Hippocampus; HMGB1 Protein; Immunologic Factors; Kaini | 2018 |
Effect of celecoxib on anticonvulsant activity of carbamazepine against maximal electroshock-induced convulsions in mice.
Topics: Animals; Anticonvulsants; Carbamazepine; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relatio | 2008 |
Prostaglandin E(2) potentiates methylmalonate-induced seizures.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Electrodes, I | 2012 |
Pharmacology of celecoxib in rat brain after kainate administration.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; | 2002 |
Anticonvulsant action of celecoxib (alone and in combination with sub-threshold dose of phenytoin) in electroshock induced convulsion.
Topics: Animals; Anticonvulsants; Celecoxib; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combin | 2003 |
Post-treatment, but not pre-treatment, with the selective cyclooxygenase-2 inhibitor celecoxib markedly enhances functional recovery from kainic acid-induced neurodegeneration.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Celecoxib; Cell | 2004 |
Celecoxib does not induce convulsions nor does it affect GABAA receptor binding activity in the presence of new quinolones in mice.
Topics: Animals; Celecoxib; Male; Mice; Protein Binding; Pyrazoles; Quinolones; Receptors, GABA-A; Seizures; | 2005 |
Cyclooxygenase-2/PGE2 pathway facilitates pentylenetetrazol-induced seizures.
Topics: Analysis of Variance; Animals; Antibodies; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; D | 2008 |
Altered GABAergic neurotransmission is associated with increased kainate-induced seizure in prostaglandin-endoperoxide synthase-2 deficient mice.
Topics: Analysis of Variance; Animals; Autoradiography; Celecoxib; Chromatography, High Pressure Liquid; Cyc | 2008 |